Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal Cancer and their median survival time: A Cohort study

Journal of Research in Medical Sciences

Volumn 19, Issue 9, 2014, Pages 850-854

  Ahmadi, Ali ^a   Mobasheri, Mahmoud ^a   Hashemi Nazari, Seyed Saeed ^b   Baradaran, Azar ^c   Choobini, Zahra Molavi ^a  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Diabetes; Hypertension; Survival time

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; COHORT ANALYSIS; COLORECTAL CANCER; COLUMN CHROMATOGRAPHY; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SOCIOECONOMICS; SURVIVAL TIME; TUMOR VOLUME;

EID: 84913537020     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hosseinzadeh A, Darae AR. Environmental factors associated with sporadic colorectal cancer. Health Syst Res J 2012;8:229-35.
2. Mohammdzadeh M, Maghbouli L, Ahmadi Dashatan R. Prevalence of risk factors of rectal cancer among 100 patients referred to radiotherapy department of Emam Reza University Hospital at Tabriz University of Medical Sciences-Tabriz. Iran. J Tabriz Univ Med Sci 2013;35:84-9.
3. Akhoond MR, Kazemnejad A, Hajizadeh E, GAnbary Motlagh A, Zali MR. Comparison of influential factors affecting survival of patients with colon and rectum cancer using competing risks model. Koomesh 2011;12:119-28.
4. Asghari-Jafarabadi M, Hajizadeh E, Kazemnejad A, Fatemi SR. Recognition of the factors affecting survival in colon and rectal cancer patients referred to RCGLD center of Shahid Beheshti University of Medical Sciences: Accelerated failure time parametric survival analysis with frailty. J Shahrekord Univ Med Sci 2010;12:51-64.
5. Hajivandi A, Amiri M. World kidney day 2014: Kidney disease and elderly. J Parathyr Dis 2014;2:3-4.
6. Nasri H. Impact of diabetes mellitus on parathyroid hormone in hemodialysis patients. J Parathyr Dis 2013;1:9-11.
7. Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyr Dis 2013;1:13-4.
8. Hajivandi A, Amiri M. World diabetes day: Diabetes mellitus and nephrology. J Nephropharmacol 2013;2:31-2.
9. Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Vitamin D therapy in diabetic kidney disease; current knowledge on a public health problem. J Parathyr Dis 2014;2:15-7.
10. Tamadon MR. Secondary hyperparathyroidism and chronic kidney disease. J Parathyr Dis 2013;1:15-6.
11. Ahmadi A, Hasanzadeh J, Rajaefard A. To determine the relative factors on hypertension in Kohrang, Chaharmahal and Bakhtiari Province, 2007. Iran J Epidemiol 2008;4:19-25.
12. Ahmadi A, Hasanzadeh J, Ghaem H, Khosravi S, Reisi R. The survey of family history of diabetes in patients with type 2 diabetes in Chaharmahal va Bakhteyari province, Iran, 2008. J Shahrekord Univ Med Sci 2009;11:1-7.
13. Brauer PM, McKeown-Eyssen GE, Jazmaji V, Logan AG, Andrews DF, Jenkins D, et al. Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. Am J Epidemiol 2002;156:702-13.
14. Fateh S, Amini M. An epidemiologic study of colorectal cancer in arak during 1994-2004 Persian. Iran J Surg 2008;2:11-7.
15. Mehrabani D, Almasi-Hashiani A. Evaluation of the 5-year survival rate and demographic factors in colorectal cancer patients. J Zanjan Univ Med Sci 2012;20:12-21.
16. Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol 2013;2013:583786.
17. Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases. Am J Cancer 1932;16:227-50.
18. Bell ET. Carcinoma of pancreas. I. Clinical and pathologic study of 600 necropsied cases. II. Relation of carcinoma of pancreas to diabetes mellitus. Am J Pathol 1957;33:499-523.
19. Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-9.
20. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
21. O’Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: A multisite case-control study. J Chronic Dis 1985;38:435-41.
22. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
23. La Vecchia C, D’Avanzo B, Negri E, Franceschi S. History of selected diseases and the risk of colorectal cancer. Eur J Cancer 1991;27:582-6.
24. Hardell L, Fredrikson M, Axelson O. Case-control study on colon cancer regarding previous diseases and drug intake. Int J Oncol 1996;8:439-44.
25. Potter JD. Reconciling the epidemiology, physiology, and molecular biology of colon cancer. JAMA 1992;268:1573-7.
26. Iber FL, Parveen S, Vandrunen M, Sood KB, Reza F, Serlovsky R, et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in long-standing diabetes. Dig Dis Sci 1993;38:45-50.
27. Mayne N. Neuropathy in the diabetic and non-diabetic populations. Lancet 1965;2:1313-6.
28. Janatuinen E, Pikkarainen P, Laakso M, Pyörälä K. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993;28:427-32.
29. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: Another complication of diabetes mellitus? Am J Epidemiol 1998;147:816-25.
30. Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer 2012;106:1718-21.
31. Othman NH, Zin AA. Association of colorectal carcinoma with metabolic diseases; experience with 138 cases from Kelantan, Malaysia. Asian Pac J Cancer Prev 2008;9:747-51.
32. Fung TT, Hu FB, Wu K, Chiuve SE, Fuchs CS, Giovannucci E. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer. Am J Clin Nutr 2010;92:1429-35.
33. Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327.
34. Österlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 2011;104:599-604.
35. Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, et al. Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi 2011;131:1251-7.
36. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011;68:1207-13.
37. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-30.
38. Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer 2009;40:101-8.